Silvijus Abramavičius1, Alina Stundžienė2, Laura Korsakova3, Mantas Venslauskas4, Edgaras Stankevičius5. 1. Laboratory of Preclinical Drug Investigation, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania. Silvijus.Abramavicius@lsmu.lt. 2. School of Economics and Business, Kaunas University of Technology, Kaunas, Lithuania. 3. Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 4. Institute of Mechatronics, Kaunas University of Technology, Kaunas, Lithuania. 5. Laboratory of Preclinical Drug Investigation, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Abstract
BACKGROUND: Investments in pharmaceutical companies remain challenging due to the inherent uncertainties of risk assessment. OBJECTIVES: Our paper aims to assess the impact of the drug development setbacks (DDS) on the stock price of pharmaceutical companies while taking into account the company's financial situation, pipeline size and trend of the stock price before the DDS. METHODS: The model-based clustering based on finite Gaussian mixture modeling was employed to identify the clusters of pharmaceutical companies with homogenous parameters. An artificial neural network was constructed to aid the prediction of the positive mean rate of return 120 days after the DDS. RESULTS: Our results reveal that a higher pipeline size and a lower rate of return before the DDS, as well as a lower ratio of the market value of the equity and the book value of the total liabilities, are associated with a positive mean rate of return 120 days after the DDS. CONCLUSION: In general, the DDS have a negative impact on the company's stock price, but this risk can be minimized by investors choosing the companies that satisfy certain criteria. Graphical abstract The higher pipeline size(spip) and lower rate of return before (srr) the drug development setback (DDS) and the Market Value of Equity/Book Value of Total Liabilities ratio (sx4) are associated with a positive mean rate of return 120 days after the DDS.
BACKGROUND: Investments in pharmaceutical companies remain challenging due to the inherent uncertainties of risk assessment. OBJECTIVES: Our paper aims to assess the impact of the drug development setbacks (DDS) on the stock price of pharmaceutical companies while taking into account the company's financial situation, pipeline size and trend of the stock price before the DDS. METHODS: The model-based clustering based on finite Gaussian mixture modeling was employed to identify the clusters of pharmaceutical companies with homogenous parameters. An artificial neural network was constructed to aid the prediction of the positive mean rate of return 120 days after the DDS. RESULTS: Our results reveal that a higher pipeline size and a lower rate of return before the DDS, as well as a lower ratio of the market value of the equity and the book value of the total liabilities, are associated with a positive mean rate of return 120 days after the DDS. CONCLUSION: In general, the DDS have a negative impact on the company's stock price, but this risk can be minimized by investors choosing the companies that satisfy certain criteria. Graphical abstract The higher pipeline size(spip) and lower rate of return before (srr) the drug development setback (DDS) and the Market Value of Equity/Book Value of Total Liabilities ratio (sx4) are associated with a positive mean rate of return 120 days after the DDS.
Entities:
Keywords:
Drug development setbacks; Investment risk assessment; Pharmaceutical companies; Stock price
Authors: Vibeke Strand; Giampiero Girolomoni; Martin Schiestl; Robert Ernst Mayer; Hilke Friccius-Quecke; Mark McCamish Journal: Curr Med Res Opin Date: 2017-02-07 Impact factor: 2.580
Authors: Richard T Thakor; Nicholas Anaya; Yuwei Zhang; Christian Vilanilam; Kien Wei Siah; Chi Heem Wong; Andrew W Lo Journal: Nat Biotechnol Date: 2017-12-08 Impact factor: 54.908
Authors: Cedric Popa; Karel Holvoet; Tessa Van Montfort; Floris Groeneveld; Steven Simoens Journal: Front Pharmacol Date: 2018-10-01 Impact factor: 5.810